CD19 and mantle cell lymphoma: Ibrutinib, a bruton tyrosine kinase inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia, was also shown to increase CD19-CAR-T cell fitness against leukemia (129, 130).